[Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].
D000547:Amantadine / Q000009:adverse effects; D000777:Anesthetics; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000928:Antidepressive Agents / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects; D000978:Antiparkinson Agents / Q000009:adverse effects*; D001532:Atropa belladonna / Q000009:adverse effects; D003863:Depression / Q000188:drug therapy; D004295:Dihydroxyphenylalanine / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007049:Iatrogenic Disease / Q000139:chemically induced*; D010276:Parasympatholytics / Q000009:adverse effects; D010300:Parkinson Disease / Q000188:drug therapy*; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011736:Pyridoxine / Q000009:adverse effects; D013566:Sympathomimetics / Q000009:adverse effects; D014149:Tranquilizing Agents / Q000009:adverse effects; D014326:Tropanes / Q000009:adverse effects
D000777:Anesthetics; D000900:Anti-Bacterial Agents; D000928:Antidepressive Agents; D000959:Antihypertensive Agents; D000978:Antiparkinson Agents; D010276:Parasympatholytics; D013566:Sympathomimetics; D014149:Tranquilizing Agents; D014326:Tropanes; D004295:Dihydroxyphenylalanine; D000547:Amantadine; D011736:Pyridoxine
Zur differentiellen Therapie des Morbus Parkinson unter besonderer Berücksichtigung von iatrogenen Schädigungsmöglichkeiten